The Anti-Inflammatory Effect of Zhibaidihuang Decoction on Recurrent Oral Ulcer with Sirt1 as the Key Regulatory Target

Figure 1

AZC model and protective effect on oral mucosa of ZBDHD treatments. (a) Ulcer (indicated by the black arrow) in oral mucosa of AZC model rat. (b–f) Histopathologic study of oral mucosa stained by hematoxylin and eosin (H&E) (x200); Ct, AZC, ZBDHD-H, ZBDHD-M, and ZBDHD-L indicated control, AZC model, high-dose ZBDHD treatment (2 g/mL), middle-dose ZBDHD treatment (1 g/mL), and low-dose ZBDHD treatment (0.5 g/mL), respectively.

(a)

(b)

(c)

(d)

(e)

(f)